Sugi Predict

Sugi Predict / Compounds / SCHEMBL2268702

SCHEMBL2268702

SCHEMBL2268702

O=C1Nc2ccc(F)cc2C12CC2

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.63
▸ MAPT P10636 1/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ KMT2A Q03164 1/20 0.58
▸ PGR P06401 7/20 0.53
▸ EPHX2 P34913 1/20 0.44
▸ AKR1B1 P15121 3/20 0.44
▸ PDE4A P27815 3/20 0.44
▸ PDE4B Q07343 3/20 0.44
▸ PDE4C Q08493 3/20 0.44
▸ PDE4D Q08499 3/20 0.44
▸ PDE3B Q13370 3/20 0.44
▸ PDE3A Q14432 3/20 0.44
▸ HTR1A P08908 1/20 0.43
▸ HTR2A P28223 1/20 0.43
▸ HTR7 P34969 1/20 0.43
▸ HTR6 P50406 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29609794 0.93 PGR (0.58) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL25399999 0.93 PGR (0.58) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL4715658 0.91 PGR (0.59) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL1950989 0.90 CYP1A2 (0.53) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL23778368 0.90 CYP1A2 (0.53) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL15649741 0.89 EPHX2 (0.59) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL16858420 0.85 TNKS (0.51) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL29860095 0.85 TNKS (0.51) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL8321443 0.83 HTR7 (0.49) CYP1A2MAPTCYP2C19KMT2APGR
SCHEMBL4982133 0.82 IP6K1 (0.54) CYP1A2MAPTCYP2C19KMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024140401-A1 HETEROCYCLIC COMPOUND ACTING AS KINASE INHIBITOR, AND COMPOSITION COMPRISING SAME 捷思英达控股有限公司 2024-07-04 — — WO disclosed
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) 2024-05-09 — — US disclosed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 — — EP disclosed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 — — EP disclosed
CN-116997550-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof 杭州普洛药物研究院有限公司 2023-11-03 — — CN disclosed
CN-114853659-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof 普洛药业股份有限公司 2022-08-05 — — CN disclosed
US-10189838-B2 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMAN-LA ROCHE INC. (US) 2019-01-29 — — US disclosed
US-20180072726-A9 NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2018-03-15 — — US disclosed
US-20160068531-A1 NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2016-03-10 — — US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 — — US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 — — US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 — — US disclosed
WO-2011092293-A2 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068531-A1 NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ZC3HAV1, IDO1, AZI2 CYP1A2 362/4885MAPT 4796/4885CYP2C19 317/4885
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF ITGB7, ITGB4, ITGA4 CYP1A2 1699/4885MAPT 2253/4885CYP2C19 815/4885
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS CRHR1, CRHR2, CRH CYP1A2 1703/4885MAPT 4066/4885CYP2C19 1024/4885
US-20180072726-A9 NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ZC3HAV1, IDO1, AZI2 CYP1A2 362/4885MAPT 4796/4885CYP2C19 317/4885
US-10189838-B2 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection IDO1, ZC3HAV1, AZI2 CYP1A2 298/4885MAPT 4826/4885CYP2C19 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.